PDRN vs PRP vs exosomes: what is actually supported in skin rejuvenation?

Three regenerative treatments dominate the "next-generation skin rejuvenation" conversation in 2026: platelet-rich plasma (PRP), exosomes, and polydeoxyribonucleotide (PDRN). All three are marketed as alternatives or upgrades to each other. All three are paired with microneedling in clinical practice. None of them are interchangeable, and the gap between marketing claims and regulatory reality is wide — especially for exosomes.

This article compares the three by mechanism, clinical evidence, regulatory status, cost, and realistic patient expectations. The goal is not to declare a winner. It is to give patients and providers enough information to match the right biologic to the right clinical situation — and to know when the evidence does not support the claim.

What each one is

PRP (Platelet-Rich Plasma) is an autologous blood product. The patient's blood is drawn, centrifuged to concentrate platelets (which contain growth factors including PDGF, TGF-β, VEGF, and EGF), and the platelet-rich fraction is reapplied — typically topically during or after microneedling, or injected intradermally. Because it comes from the patient's own body, the allergy and disease-transmission risk is essentially zero. PRP has been used in medicine for wound healing since the 1970s and in dermatology since the early 2000s.

Exosomes are extracellular vesicles — nano-sized lipid-bound packets (30–150 nm) produced by cells, containing signaling molecules including growth factors, cytokines, lipids, messenger RNA, and microRNA. In aesthetic practice, exosomes are derived from mesenchymal stem cells (typically human or plant sources), manufactured in commercial facilities, and applied topically (often during or after microneedling or laser) or, in some markets, injected. They are not derived from the patient's own body.

PDRN (Polydeoxyribonucleotide) is a low-molecular-weight DNA polymer extracted from the sperm of salmon species (Oncorhynchus keta and Oncorhynchus mykiss). It activates tissue repair through adenosine A2A receptor stimulation, promoting wound healing, angiogenesis, and anti-inflammatory responses. PDRN has been used in regenerative medicine since the 1990s — approved by the Italian Medicines Agency (AIFA) in 1994 for wound healing — and is now widely used in aesthetic dermatology in South Korea and parts of Europe.

Mechanism: how each one works

The three biologics operate through fundamentally different pathways:

The key distinction is that PRP delivers a concentrated bolus of the patient's own growth factors. Exosomes deliver a manufactured cocktail of signaling molecules from an external source. PDRN delivers DNA fragments that stimulate repair through a specific receptor pathway. All three ultimately aim to stimulate fibroblasts and promote tissue regeneration — but they reach that goal through different molecular routes.

Evidence: what the clinical literature actually shows

PRP — strongest evidence base

PRP has the most extensive clinical literature of the three. A 2026 review in Our Dermatology Online (Regenerative Biologics Aging Skin) concluded that "PRP remains the most validated option for routine clinical use" with "reproducible growth-factor stimulation and strong safety." Multiple systematic reviews and RCTs support PRP for:

• Skin rejuvenation and texture improvement when combined with microneedling
• Acne scar improvement
• Hair restoration (androgenetic alopecia)
• Accelerated wound healing post-procedure

The quality of PRP is variable — it depends on the patient's platelet count, age, health status, and the centrifuge protocol used. A 25-year-old patient's PRP contains more robust growth factors than a 65-year-old's. This is a limitation of autologous products: they reflect the patient's own biology.

Exosomes — compelling biology, limited clinical data

Exosomes have generated the most excitement and the most marketing hype. A 2025 split-face, investigator-blinded trial (PMC12104007) compared exosomes to PRP for photoaged facial skin. Results showed that both treatments improved wrinkling, dyschromia, erythema, and texture, with exosomes showing "slightly greater improvement in wrinkling, erythema, and texture" at 6 months. However, the study had a small sample size and acknowledged the need for "larger clinical trials including individuals from a variety of ages and health statuses."

A separate review in the Journal of Drugs in Dermatology (2025;24(1):12-18) found that while there is "biological rationale for skin and hair benefits," there remain "major gaps in standardization and clinical data" and "robust long-term clinical trials are lacking."

The Our Dermatology Online review placed exosomes as having "compelling biological potential" but noted they are "constrained by standardization and regulatory gaps."

Critical limitation: Exosome quality varies enormously between manufacturers. Different studies use varying exosome sources, concentrations, and delivery methods. There is no standardized dosing, no standardized potency assay, and no agreed-upon treatment protocol. This makes it impossible to compare results across studies or to know whether the product used in one study is comparable to the product a clinic is offering.

PDRN — growing evidence, particularly in Asian and European markets

PDRN has a longer clinical track record than exosomes — it has been used in wound healing since the 1990s and in aesthetic medicine for over a decade in South Korea and Italy. A recent comparative study showed microneedling with PDRN produced "more significant wrinkle reduction" compared to microneedling with PRP, though both were effective for mild-to-moderate wrinkles and hyperpigmentation.

PDRN's anti-inflammatory mechanism makes it particularly suited for:

• Sensitive or reactive skin
• Post-inflammatory hyperpigmentation
• Skin barrier repair
• Accelerated healing after laser or energy-based procedures

The 2025 Applied Sciences review (MDPI, 15(19):10437) documented PDRN's clinical applications for wrinkles, dryness, hyperpigmentation, hair loss, and barrier dysfunction. However, most studies originate from South Korea and Italy, and large-scale RCTs in diverse populations are still limited.

Regulatory status — the most important difference

This is where the three treatments diverge dramatically, and where patients are most often misled by marketing.

PRP — well-established regulatory position

PRP is an autologous blood product. The FDA's position on autologous PRP used within the same procedure (same patient, same visit, minimal manipulation) is well established. PRP does not require FDA approval because it meets the criteria for a same-procedure exception under 21 CFR Part 1271. The regulatory framework is clear, and the safety profile is documented across decades of use in orthopedics, wound care, and dermatology.

Exosomes — zero FDA approvals, active enforcement

The regulatory reality for exosomes is unambiguous: there are currently no FDA-approved exosome products for any therapeutic or cosmetic use in humans. The FDA has stated this in its public safety notification and in every warning letter issued to exosome manufacturers and distributors.

Key regulatory facts as of 2026:

• The FDA classifies exosome products as drugs and biological products under the Public Health Service Act and the Federal Food Drug & Cosmetic Act
• Pre-market approval (IND application and clinical trials) is required before any therapeutic claims can be made
• The FDA issued a public safety notification in 2020 warning about unapproved exosome products, citing reports of serious adverse events including infections
• Multiple FDA warning letters have been sent to exosome manufacturers (including Kimera Labs in 2023)
• The California Medical Board has warned licensees that administering unapproved exosome products constitutes unprofessional conduct outside the standard of care
• Even topical application of exosomes following microneedling is considered systemic administration by the FDA, not cosmetic use, and therefore requires drug approval
• A CEO of an unapproved biologics firm received a 36-month federal prison sentence
• Facility registration (which some exosome companies cite) is an administrative filing requirement and does not constitute product approval

The Journal of Drugs in Dermatology review (2025) explicitly stated: "no exosome products are FDA-approved for cosmetic dermatology, and the evolving regulatory landscape means many commercially available preparations remain unstandardized."

Patients considering exosome treatments should understand: the clinic offering the treatment is using an unapproved product. The safety and efficacy data are limited and non-standardized. The legal and regulatory risk falls on both the provider and the patient.

PDRN — approved in some countries, not in the US for aesthetic injection

PDRN was approved by the Italian Medicines Agency (AIFA) in 1994 for wound healing. PDRN-based dermal fillers are approved in South Korea and several other countries. In the United States, PDRN is not FDA-approved for injection. Topical PDRN products are available as cosmetics, but injectable PDRN is not legally marketed in the US.

Patients seeing "PDRN" on a US clinic menu are most likely being offered an off-label or imported product. The regulatory status is less precarious than exosomes (because PDRN has established pharmaceutical approval in other jurisdictions), but US patients should still ask whether the product has FDA clearance for the intended use.

Cost comparison

Exosomes are the premium-priced option, reflecting manufacturing costs and marketing investment. PRP pricing reflects the in-office blood draw and processing but no external product cost. PDRN is typically priced between the two.

Matching the treatment to the patient

No single biologic is best for every patient. The decision should be driven by the clinical situation, the patient's risk tolerance for unregulated products, and the evidence supporting the intended use.

What to ask your provider

Before any regenerative skin treatment:

• What biologic are you using — PRP, exosomes, or PDRN?
• If exosomes: is this product FDA-approved? (The answer should be "no." If the provider says yes, find another provider.)
• If PDRN: is this product approved in the US for the intended use? What country is it sourced from?
• What is the evidence for using this treatment for my specific concern?
• How many sessions do you recommend, and what is the total cost?
• What results should I realistically expect, and over what timeline?
• What are the risks, and how are they managed?

The bottom line

PRP is the evidence leader — the most studied, the safest regulatory position, the longest track record. It is limited by the patient's own biology (age and health affect growth factor quality) but remains the standard of care for biologic-augmented skin rejuvenation.

Exosomes have the most exciting biological story but the weakest clinical evidence and the most problematic regulatory status. No exosome product is FDA-approved. The manufacturing is non-standardized. The marketing claims routinely outpace the data. Patients should be cautious and should receive explicit disclosure that these are unapproved products.

PDRN is the middle ground — established pharmaceutical approval in some countries, growing evidence base, particularly strong for anti-inflammatory indications, but not FDA-approved for aesthetic injection in the US.

The right treatment depends on what the patient needs, what the evidence supports, and what the regulatory framework permits. The wrong treatment is the one chosen because of marketing rather than mechanism.

Related treatments you may encounter

Three additional regenerative options appear alongside PRP, exosomes, and PDRN in clinical marketing:

PRF (Platelet-Rich Fibrin) is a second-generation autologous blood product. Unlike PRP, which uses anticoagulants to keep the platelets suspended, PRF is processed without anticoagulants, producing a fibrin matrix that releases growth factors more slowly over 7–10 days. PRF is used for tear-trough hollowing, fine lines, and as a bio-filler (PRF EZ Gel). Its regulatory position is similar to PRP — autologous, same-procedure, minimal manipulation.

PDGF (Platelet-Derived Growth Factor, recombinant) — branded as Ariessence (rhPDGF-BB) — is a lab-manufactured, single growth factor product that delivers consistent potency regardless of patient age or health. It is applied topically after microneedling or injected off-label. Because it is a recombinant protein rather than a cell-derived biologic, it avoids some of the regulatory ambiguity of exosomes, though its specific aesthetic indications are still limited.

Skinvive (hyaluronic acid skin booster, FDA-approved for cheek hydration) is a different category — not regenerative but hydrating — and is sometimes compared in the same conversation. Our filler longevity article covers HA-based skin boosters in more detail.

These are not substitutes for PRP, exosomes, or PDRN. They address different mechanisms and different patient needs. The same framework applies: match the mechanism to the clinical indication, verify the regulatory status, and demand evidence before accepting marketing claims.

Sources

• Exosomes, MSC secretome, and PRP: comparative review. Our Dermatology Online. 2026;2:21 — https://www.odermatol.com/issue-in-html/2026-2-21-regenerative_aging_skin/
• Adipose MSC-derived exosomes vs PRP: investigator-blinded split-face trial. PMC12104007 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12104007/
• Exosomes in cosmetic dermatology: review of benefits and challenges. J Drugs Dermatol. 2025;24(1):12-18. doi:10.36849/JDD.8872 — https://jddonline.com/exosomes-in-cosmetic-dermatology-a-review-of-benefits-and-challenges-2/
• FDA consumer alert on regenerative medicine products including exosomes — https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
• FDA public safety alert on unapproved exosome products — https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products
• Exosome therapy FDA status 2026: zero approvals — https://unicornbioscience.com/exosome-therapy-fda-status-2026/
• FDA regulations on exosome products in 2026: physician guide — https://bioregenex.com/fda-regulations-exosome-products-2026-physician-guide/
• PDRN: pharmacological activity and clinical use. PMC5405115 — https://pmc.ncbi.nlm.nih.gov/articles/PMC5405115/
• Polydeoxyribonucleotides as emerging therapeutics for skin diseases. Appl Sci. 2025;15(19):10437 — https://www.mdpi.com/2076-3417/15/19/10437
• Polynucleotides and PDRN in dermatology: narrative review — https://jcasonline.com/polynucleotides-and-polydeoxyribonucleotides-in-dermatology-a-narrative-review/
• PDRN skin regeneration and barrier improvement: PMC10649580 — https://pmc.ncbi.nlm.nih.gov/articles/PMC10649580/